Management of Osteoarthritis: Expert Opinion on NSAIDs
Open accessThe DOI matches its Crossref record; 103 of the 106 references it cites were found in a registry or an index.
Abstract
Osteoarthritis (OA) is a leading cause of disability among older adults worldwide. Treatment aims are to alleviate inflammatory pain and improve physical function through non-pharmacological and pharmacological interventions. Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line therapy. However, selection is challenged by patient age, comorbidities and polypharmacy, and by the drug's benefit/risk balance, all of which together influence the risk of cardiovascular (CV), gastrointestinal (GI) and renal adverse events (AEs). While the efficacy profile of the various NSAIDs is delineated, the differences in their safety profile are not straightforward. This narrative review provides practical indications by a multidisciplinary Italian expert panel for general practitioners and specialists managing OA patients with chronic inflammatory pain; the goal is to maximize therapy efficacy while reducing untoward effects caused by inappropriate NSAID use. The discussion on the best approach to NSAIDs spanned the following topics: (1) patient evaluation: investigate pain origin, duration and components together with possible risk factors for CV, GI and renal AEs; (2) non-pharmacological interventions: the physiatrist provides a person-centered, holistic approach accounting for all patient aspects; (3) pharmacological interventions: patient profile and drugs' pharmacological properties affect NSAID selection, which drugs to be used in combination or to be avoided, formulation and therapy duration; (4) the pharmacologist's, general practitioner's and pain therapist's points of view; (5) NSAID safety: the individual baseline risk and the drug's safety profile are major determinants of CV, GI and renal risk; consider possible drug-drug interactions; (6) periodical re-evaluation of treatment response and adherence, using scales to assess pain and function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, constipation from calcium supplements, insomnia from selective serotonin reuptake inhibitors (SSRIs), and depression from beta-blockers can all be managed through tailored exercise [[548], [549], [550], [551], [552]]”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [549]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
da Costa, B. R., Reichenbach, S., Keller, N., Nartey, L., Wandel, S., Jüni, P., & Trelle, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31744-0 · Cited by 522 · cited 5×
“Among these, the network meta-analysis by da Costa and colleagues, comparing the effectiveness of various NSAIDs, paracetamol and placebo on pain and physical function improvement, included the highest number of preparations and doses and provided also information on the dose–response relation [21].”
BackgroundInfluentialRetractedda Costa, B. R., Reichenbach, S., Keller, N., Nartey, L., Wandel, S., Jüni, P., & Trelle, S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30002-2 · Cited by 418
RetractedEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290 · cited 2×
“Patients are considered at high risk when the score of the 10-year fatal CV disease (CVD) risk is 5–10% or if they have familial dyslipidemia, severe hypertension, diabetes without CV risk factors and organ damage or moderate chronic renal failure [46, 47].”
BackgroundMethodHawker, G. A., Mian, S., Kendzerska, T., & French, M. (2011) · Arthritis Care & Research · doi:10.1002/acr.20543 · Cited by 4,924
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., Arden, N. K., Bennell, K., Bierma-Zeinstra, S. M. A., Kraus, V. B., Lohmander, L. S., Abbott, J. H., Bhandari, M., et al. (2019) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2019.06.011 · Cited by 3,542
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N. B., First, M. B., et al. (2019) · Pain · doi:10.1097/j.pain.0000000000001384 · Cited by 3,478 · cited 2×
“The IASP describes three types of pain: nociceptive, neuropathic and nociplastic [34].”
BackgroundManagement of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312288 · Cited by 2,946 · cited 1×
“Thus, the most recent international guidelines recommend that patients be tested for the presence of the infection and, if present, to eradicate it in those who have to start a prolonged therapy with NSAIDs [79].”
BackgroundBouhassira, D., Attal, N., Alchaar, H., Boureau, F., Brochet, B., Bruxelle, J., Cunin, G., Fermanian, J., Ginies, P., Grun-Overdyking, A., et al. (2005) · Pain · doi:10.1016/j.pain.2004.12.010 · Cited by 2,741 · cited 1×
“The most used tools to discriminate neuropathic pain from non-neuropathic pain in clinical settings include painDETECT [36], the Leeds assessment of neuropathic symptoms and signs Pain Scale [37] and the Douleur Neuropathique 4 questions [38]; all of these tools rely on the description of pain and on the bedside exami…”
MethodKolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24131 · Cited by 2,516
Freynhagen, R., Baron, R., Gockel, U., & Tölle, T. R. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132488 · Cited by 2,280 · cited 1×
“The most used tools to discriminate neuropathic pain from non-neuropathic pain in clinical settings include painDETECT [36], the Leeds assessment of neuropathic symptoms and signs Pain Scale [37] and the Douleur Neuropathique 4 questions [38]; all of these tools rely on the description of pain and on the bedside exami…”
MethodRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741 · cited 1×
“Although COX-2-selective NSAIDs (coxibs) were initially introduced as a safer alternative to tNSAIDs, their use has been associated to a high risk of CV events [12].”
BackgroundThe LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs
Bennett, M. (2001) · Pain · doi:10.1016/s0304-3959(00)00482-6 · Cited by 1,164 · cited 1×
“The most used tools to discriminate neuropathic pain from non-neuropathic pain in clinical settings include painDETECT [36], the Leeds assessment of neuropathic symptoms and signs Pain Scale [37] and the Douleur Neuropathique 4 questions [38]; all of these tools rely on the description of pain and on the bedside exami…”
MethodGarcía Rodríguez, L., & Jick, H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91843-0 · Cited by 975 · cited 1×
“Both in patients at low and high risk, diclofenac and coxibs yielded a similar risk (in low-risk patients: 2 per 1000; in high-risk patients: 6 per 1000, respectively) that was lower than that of ibuprofen and naproxen (in low-risk patients: 4 per 1000; in high-risk patients: 15 and 16 per 1000, respectively), in line…”
ResultRisks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
Langman, M. J. S., Weil, J., Wainwright, P., Lawson, D. H., Rawlins, M. D., Logan, R. F. A., Murphy, M., Vessey, M. P., & Colin-Jones, D. G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90185-6 · Cited by 872 · cited 1×
“Both in patients at low and high risk, diclofenac and coxibs yielded a similar risk (in low-risk patients: 2 per 1000; in high-risk patients: 6 per 1000, respectively) that was lower than that of ibuprofen and naproxen (in low-risk patients: 4 per 1000; in high-risk patients: 15 and 16 per 1000, respectively), in line…”
ResultCardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Nissen, S. E., Yeomans, N. D., Solomon, D. H., Lüscher, T. F., Libby, P., Husni, M. E., Graham, D. Y., Borer, J. S., Wisniewski, L. M., Wolski, K. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611593 · Cited by 856
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804 · cited 2×
“The excess number of events depends on the underlying risk of the patient, the relative risk of the drug and the duration of the followup [58].”
BackgroundYeomans, N. D., Tulassay, Z., Juhász, L., Rácz, I., Howard, J. M., van Rensburg, C. J., Swannell, A. J., & Hawkey, C. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381104 · Cited by 767 · cited 1×
“PPIs have to be administered throughout the period of NSAID use; even half the standard dose seems to be sufficient to achieve the benefit [94].”
BackgroundDo Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis
Johnson, A. G., Nguyen, T. V., & Day, R. O. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00011 · Cited by 717
Bruyère, O., Honvo, G., Veronese, N., Arden, N. K., Branco, J., Curtis, E. M., Al-Daghri, N. M., Herrero-Beaumont, G., Martel-Pelletier, J., Pelletier, J.-P., et al. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.008 · Cited by 695 · cited 1×
“The goal of treatment in OA is to reduce pain intensity and improve function and quality of life through a combination of non-pharmacological and pharmacological interventions [5, 6].”
BackgroundParacetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674 · cited 19×
“NSAIDs comprise non-selective drugs, such as ibuprofen and naproxen, and selective COX-2 inhibitors (i.e. coxibs), such as etoricoxib and celecoxib.”
BackgroundInfluentialBannuru, R. R., Schmid, C. H., Kent, D. M., Vaysbrot, E. E., Wong, J. B., & McAlindon, T. E. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1231 · Cited by 623
Osteoarthritis year in review 2019: epidemiology and therapy
Kloppenburg, M., & Berenbaum, F. (2020) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2020.01.002 · Cited by 532 · cited 1×
“Osteoarthritis (OA) is the most frequent form of arthritis worldwide and a leading cause of disability among older adults [1].”
BackgroundBally, M., Dendukuri, N., Rich, B., Nadeau, L., Helin-Salmivaara, A., Garbe, E., & Brophy, J. M. (2017) · BMJ · doi:10.1136/bmj.j1909 · Cited by 528 · cited 1×
“A recent meta-analysis of individual patient data in real-world settings [30] has shown that all traditional NSAIDs are associated with an increased risk of AMI, similar to that reported with celecoxib therapy.”
ResultA Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure
Pope, J. E. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410040045007 · Cited by 527
The Mechanisms of Action of NSAIDs in Analgesia
Cashman, J. N. (1996) · Drugs · doi:10.2165/00003495-199600525-00004 · Cited by 505
Epidemiology of NSAID induced gastrointestinal complications.
Singh, G., & Triadafilopoulos, G. (1999) · PubMed · Cited by 492
2018 update of the EULAR recommendations for the management of hand osteoarthritis
Kloppenburg, M., Kroon, F. P., Blanco, F. J., Doherty, M., Dziedzic, K. S., Greibrokk, E., Haugen, I. K., Herrero-Beaumont, G., Jonsson, H., Kjeken, I., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213826 · Cited by 489
New insights into the use of currently available non-steroidal anti-inflammatory drugs
Brune, & Patrignani, P. (2015) · Journal of Pain Research · doi:10.2147/jpr.s75160 · Cited by 469 · cited 1×
“Importantly, the kinetics of COX-1 and COX-2 inhibition are different (non-linear and linear, respectively [56]).”
Backgroundfor the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469 · cited 8×
“(4) Use PPIs in the presence of particular risk factors.”
BackgroundInfluentialGislason, G. H., Jacobsen, S., Rasmussen, J. N., Rasmussen, S., Buch, P., Friberg, J., Schramm, T. K., Abildstrom, S. Z., Køber, L., Madsen, M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.616219 · Cited by 447 · cited 1×
“mortality has been estimated to be approximately six deaths per 100 person-years of treatment with a COX-2 inhibitor compared with no NSAID treatment [67].”
BackgroundEffect of ibuprofen on cardioprotective effect of aspirin
MacDonald, T., & Wei, L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12509-3 · Cited by 419
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations
Edwards, R. R., Dworkin, R. H., Turk, D. C., Angst, M. S., Dionne, R., Freeman, R., Hansson, P., Haroutounian, S., Arendt-Nielsen, L., Attal, N., et al. (2016) · Pain · doi:10.1097/j.pain.0000000000000602 · Cited by 403
Topical NSAIDs for chronic musculoskeletal pain in adults
Derry, S., Conaghan, P., Da Silva, J. A. P., Wiffen, P. J., & Moore, R. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007400.pub3 · Cited by 388
Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity
Ghanem, C. I., Pérez, M. J., Manautou, J. E., & Mottino, A. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.020 · Cited by 384 · cited 1×
“analgesic with multiple effects, the main one being the stimulation of the endogenous cannabinoid system [51].”
BackgroundCastellsague, J., Riera-Guardia, N., Calingaert, B., Varas-Lorenzo, C., Fourrier-Reglat, A., Nicotra, F., Sturkenboom, M., Perez-Gutthann, S., & Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project (2012) · Drug Safety · doi:10.1007/bf03261999 · Cited by 341
Zhang, J., Ding, E. L., & Song, Y. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60015 · Cited by 332 · cited 1×
“(3) Monitor renal function and blood pressure in NSAID/coxib users, especially if they present preexisting conditions such as hypertension, renal disease and heart failure [75].”
BackgroundMeta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.5.ioi50013 · Cited by 329 · cited 1×
“In a metaanalysis of 19 RCTs including 45,000 patients with arthritis treated for[4 weeks with COX-2 inhibitors, non-selective NSAIDs or placebo, coxibs caused a weighted mean difference point estimate increase in systolic and diastolic BP compared with placebo and non-selective NSAIDs, and were associated with a non-…”
BackgroundUngprasert, P., Cheungpasitporn, W., Crowson, C. S., & Matteson, E. L. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.03.008 · Cited by 322 · cited 1×
“A meta-analysis of observational studies [28] found a statistically significant elevated AKI risk in patients treated”
BackgroundIndividual NSAIDs and Upper Gastrointestinal Complications
Castellsagué, J., Riera‐Guàrdia, N., Calingaert, B., Varas‐Lorenzo, C., Fourrier‐Réglat, A., Nicotra, F., Sturkenboom, M., & Perez‐Gutthann, S. (2012) · Drug Safety · doi:10.2165/11633470-000000000-00000 · Cited by 309
Singh, G. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440130066007 · Cited by 287 · cited 1×
“Most of the patients who develop a serious GI AE while on NSAID therapy are asymptomatic prior to the event [83], particularly the”
BackgroundZhang, X., Donnan, P. T., Bell, S., & Guthrie, B. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0673-8 · Cited by 278 · cited 1×
“Another meta-analysis of observational studies [29] reported that, in the general population, the pooled OR of AKI for ongoing NSAID exposure was 1.”
BackgroundVariability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding
Massó González, E. L., Patrignani, P., Tacconelli, S., & Rodríguez, L. A. G. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27412 · Cited by 264
Laine, L., Bombardier, C., Hawkey, C. J., Davis, B., Shapiro, D., Brett, C., & Reicin, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.36013 · Cited by 264 · cited 1×
“Among the risk factors for the onset of NSAID-associated ulcer complications (Table 1), advanced age is a primary risk factor for GI events [84]: indeed, NSAID users aged 75–89 years have a twofold higher risk of bleeding (RR 4.”
BackgroundWilcox, C. M., Cryer, B., & Triadafilopoulos, G. (2005) · PubMed · Cited by 239
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs
Patrignani, P., & Patrono, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.09.016 · Cited by 239 · cited 20×
“NSAIDs comprise non-selective drugs, such as ibuprofen and naproxen, and selective COX-2 inhibitors (i.e. coxibs), such as etoricoxib and celecoxib.”
BackgroundInfluentialM235T angiotensinogen gene polymorphism and cardiovascular renal risk
Staessen, J. A., Kuznetsova, T., Wang, J. G., Emelianov, D., Vlietinck, R., & Fagard, R. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917010-00003 · Cited by 236
For the International NSAID Consensus Group, Scarpignato, C., Lanas, A., Blandizzi, C., Lems, W. F., Hermann, M., & Hunt, R. H. (2015) · BMC Medicine · doi:10.1186/s12916-015-0285-8 · Cited by 236 · cited 1×
“NSAID users may also experience intestinal disorders, including small bowel injuries [77], which may be caused by the mucosal inflammatory pathway triggered by microbiota changes [81].”
BackgroundOsteoarthritis phenotypes and novel therapeutic targets
Van Spil, W. E., Kubassova, O., Boesen, M., Bay-Jensen, A.-C., & Mobasheri, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.02.037 · Cited by 225 · cited 3×
“Radiological imaging allows potential changes in bone, cartilage and inflammation to be monitored [35] and includes cartilage evaluation to verify possible interjoint space reduction, increased density of subchondral bone and abnormal reactive growth of the bone at the edge of joint (osteophytes).”
BackgroundInfluentialvan Walsem, A., Pandhi, S., Nixon, R. M., Guyot, P., Karabis, A., & Moore, R. A. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0554-0 · Cited by 222 · cited 3×
“Table 3 presents the results from two recent meta-analyses of RCTs that report the rate of risk for bleeding associated with tNSAIDs and coxibs versus placebo [26] and for major GI events associated with tNSAIDs and coxibs versus diclofenac [20].”
BackgroundDual acting anti-inflammatory drugs: a reappraisal
Bertolini, A., Ottani, A., & Sandrini, M. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0872 · Cited by 206
Fosbøl, E., Gislason, G., Jacobsen, S., Folke, F., Hansen, M., Schramm, T., Sørensen, R., Rasmussen, J., Andersen, S., Abildstrom, S., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.204 · Cited by 192 · cited 1×
“27], respectively), which increased in a dose-dependent fashion [68].”
BackgroundTopical NSAIDs for acute musculoskeletal pain in adults
Derry, S., Moore, R. A., Gaskell, H., McIntyre, M., & Wiffen, P. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007402.pub3 · Cited by 186
Neuropathic pain screening questionnaires have limited measurement properties. A systematic review
Mathieson, S., Maher, C. G., Terwee, C. B., de Campos, T. F., & Lin, C. C. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.03.010 · Cited by 182 · cited 1×
“Although these scales are easy to use and allow a preliminary clinical assessment, they are considered to be useful screening tools and cannot replace a thorough clinical assessment and their accuracy varies across different populations [40, 41].”
BackgroundDiclofenac use and cardiovascular risks: series of nationwide cohort studies
Schmidt, M., Sørensen, H. T., & Pedersen, L. (2018) · BMJ · doi:10.1136/bmj.k3426 · Cited by 177 · cited 1×
“Moreover, in low-risk patients, an increased risk of pooled CV events was found with lower doses of diclofenac versus paracetamol, ibuprofen and naproxen (which, however, varied based on the event considered) over 1 month; surprisingly, the relative risk decreased in patients at high CV risk [69], but the explanation…”
BackgroundProton pump inhibitors: use and misuse in the clinical setting
Savarino, V., Marabotto, E., Zentilin, P., Furnari, M., Bodini, G., De Maria, C., Pellegatta, G., Coppo, C., & Savarino, E. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1531703 · Cited by 167 · cited 1×
“they do not represent an actual risk for ulcerogenesis [87].”
BackgroundSelf-citationNon-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis
Gunter, B., Butler, K. A., Wallace, R. L., Smith, S. M., & Harirforoosh, S. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12484 · Cited by 150
Psychometric evaluation of osteoarthritis questionnaires: A systematic review of the literature
Veenhof, C., Bijlsma, J. W. J., van den Ende, C. H. M., Dijk, G. M. V., Pisters, M. F., & Dekker, J. (2006) · Arthritis Care & Research · doi:10.1002/art.22001 · Cited by 146 · cited 1×
“As for the WOMAC, it is one of the most appropriate patient-reported outcome measures to be employed in trials of knee and hip OA; however, interpretation of the results and comparisons among studies are frequently challenged by the different versions available (Likert, VAS or NRS) and by the wide variation in its use…”
BackgroundChan, C. C., Reid, C. M., Aw, T., Liew, D., Haas, S. J., & Krum, H. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283310dc9 · Cited by 146
COX-2 Selective Inhibitors in the Treatment of Osteoarthritis
Laine, L., White, W. B., Rostom, A., & Hochberg, M. C. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2007.10.004 · Cited by 141
Varas‐Lorenzo, C., Riera‐Guardia, N., Calingaert, B., Castellsague, J., Salvo, F., Nicotra, F., Sturkenboom, M., & Perez‐Gutthann, S. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3437 · Cited by 140
Kroon, F. P. B., Carmona, L., Schoones, J. W., & Kloppenburg, M. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000734 · Cited by 125 · cited 1×
“The goal of treatment in OA is to reduce pain intensity and improve function and quality of life through a combination of non-pharmacological and pharmacological interventions [5, 6].”
BackgroundMechanisms of Drug-Induced Interstitial Nephritis
Raghavan, R., & Shawar, S. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.11.004 · Cited by 117 · cited 1×
“In other instances, interstitial nephritis can occur bacause of NSAID immuno-allergic effects that are most likely unrelated to COX inhibition [97].”
BackgroundClinical outcome assessment in clinical trials of chronic pain treatments
Patel, K. V., Amtmann, D., Jensen, M. P., Smith, S. M., Veasley, C., & Turk, D. C. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000784 · Cited by 112
Goodman & Gilman's the Pharmacological Basis of Therapeutics 12 th Edition 2011
Shetty, P. A., & Dharia, H. V. (2015) · Indian Practitioner · Cited by 107
Curtis, E. M., Fuggle, N. R., Shaw, S., Spooner, L., Ntani, G., Parsons, C. M., Honvo, G., Baird, J., Maggi, S., Dennison, E. M., et al. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00664-x · Cited by 107
Osani, M. C., Vaysbrot, E. E., Zhou, M., McAlindon, T. E., & Bannuru, R. R. (2020) · Arthritis Care & Research · doi:10.1002/acr.23884 · Cited by 104 · cited 1×
“A recent study has shown that the NSAID-induced improvement in pain and function peaks at 2 weeks and starts to decline by 8 weeks, while minor CV and GI AEs occur as early as 4 weeks after the initiation of NSAID treatment [62].”
BackgroundMasclee, G. M. C., Straatman, H., Arfè, A., Castellsagué, J., Garbe, E., Herings, R. M. C., Kollhorst, B., Lucchi, S. R., Perez‐Gutthann, S., Romio, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204746 · Cited by 89
Kent, A. P., Brueckmann, M., Fraessdorf, M., Connolly, S. J., Yusuf, S., Eikelboom, J. W., Oldgren, J., Reilly, P. A., Wallentin, L., & Ezekowitz, M. D. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.063 · Cited by 83 · cited 1×
“A recent study showed that patients on anticoagulant therapy with both vitamin K antagonists and dabigatran should avoid NSAIDs due to a greater risk of hemorrhage, especially GI bleeding, and more frequent complications (such as strokes and embolisms) [71].”
BackgroundOmeprazole ameliorates aspirin-induced gastroduodenal injury
Scheiman, J. M., Behler, E. M., Loeffler, K. M., & Elta, G. H. (1994) · Digestive Diseases and Sciences · doi:10.1007/bf02090067 · Cited by 80 · cited 1×
“Unlike H2-antagonists that prevent only the onset of duodenal ulcers, PPIs can protect both the stomach, the main site of NSAID-induced damage, and the duodenum [91].”
BackgroundHansen, J., Hallas, J., Lauritsen, J., & Bytzer, P. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609031975 · Cited by 79
Copsey, B. J., Thompson, J., Vadher, K., Ali, U. M., Dutton, S., Fitzpatrick, R. M., Lamb, S. E., & Cook, J. A. (2018) · Quality of Life Research · doi:10.1007/s11136-018-1978-1 · Cited by 77 · cited 1×
“As for the WOMAC, it is one of the most appropriate patient-reported outcome measures to be employed in trials of knee and hip OA; however, interpretation of the results and comparisons among studies are frequently challenged by the different versions available (Likert, VAS or NRS) and by the wide variation in its use…”
BackgroundCoronary Risks Associated with Diclofenac and Other NSAIDs: An Update
Moore, N. D. (2020) · Drug Safety · doi:10.1007/s40264-019-00900-8 · Cited by 72 · cited 3×
“Moreover, in low-risk patients, an increased risk of pooled CV events was found with lower doses of diclofenac versus paracetamol, ibuprofen and naproxen (which, however, varied based on the event considered) over 1 month; surprisingly, the relative risk decreased in patients at high CV risk [69], but the explanation…”
BackgroundAriani, A., MANARA, M., Fioravanti, A., Iannone, F., Salaffi, F., Ughi, N., Prevete, I., Bortoluzzi, A., Parisi, S., & Scirè, C. A. (2019) · Reumatismo · doi:10.4081/reumatismo.2019.1188 · Cited by 71 · cited 4×
“particularly to exclude chronic or crystal-induced arthropathies [4].”
BackgroundMethodInfluentialMartín Arias, L. H., Martín González, A., Sanz Fadrique, R., & Vazquez, E. S. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1302 · Cited by 68
Morrison, A., Ramey, D. R., van Adelsberg, J., & Watson, D. J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x219553 · Cited by 66 · cited 2×
“No effect on blood pressure (BP) has been observed in ASA [100–102] and coxib users [103, 104].”
BackgroundMallen, S. R., Essex, M. N., & Zhang, R. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.581274 · Cited by 61
Paulus, H. E. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780311118 · Cited by 56 · cited 1×
“normal endoscopy at the upper GI tract [86].”
BackgroundPavelká, K. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.649848 · Cited by 52
Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen
Reed, G. W., Abdallah, M., Shao, M., Wolski, K., Wisniewski, L., Yeomans, N. D., Lüscher, T. F., BORER, J. S., Graham, D. Y., Husni, M. E., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.036 · Cited by 48
Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition
Scarpignato, C., & Bjarnason, I. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0726-1 · Cited by 48 · cited 2×
“Up to 70% of NSAID users experience minimal mucosal lesions as early as within a few hours of intake [77]; these may indicate gastric mucosa frailty and the tendency to become real ulcers [78].”
BackgroundJung, S., Jang, E. J., Nam, S. W., Kwon, H. H., Im, S. G., Kim, D., Cho, S., Kim, D., & Sung, Y. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1439694 · Cited by 46
Foy, M. C., Vaishnav, J., & Sperati, C. J. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.08.013 · Cited by 46 · cited 1×
“pertensive effects of NSAIDs are believed to stem from three major mechanisms [99]:”
BackgroundImpact of potential inappropriate NSAIDs use in chronic pain
Ussai, S., Miceli, L., Pisa, F., Bednarova, R., Petelin, R., Della Rocca, G., & Giordano, A. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s80686 · Cited by 44 · cited 1×
“trying to maximize therapy efficacy while reducing untoward effects caused by inappropriate NSAID use [14], a multidisciplinary expert panel (i.”
BackgroundCastellsague, J., Riera‐Guàrdia, N., Calingaert, B., Varas-lorenzo, C., Fourrier-reglat, A., Nicotra, F., Sturkenboom, M., & Perez-gutthann, S. (n.d.) · Cited by 44
Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users
Bakhriansyah, M., Souverein, P. C., van den Hoogen, M. W. F., de Boer, A., & Klungel, O. H. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14331218 · Cited by 40 · cited 1×
“Various NSAIDs have been implicated in glomerular disorders leading to proteinuria and/ or the nephrotic syndrome, possibly due to some podocyte-specific type of injury [96].”
BackgroundNSAIDs and self-medication: A serious concern
Doomra, R., & Goyal, A. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_201_20 · Cited by 39
Lefebvre, C. E., Hindié, J., Zappitelli, M., Platt, R. W., & Filion, K. B. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz054 · Cited by 35 · cited 1×
“A recent systematic review [98] noted a cross-sectional point prevalence of NSAID use of between 8 and 21% in 49,209 patients with CKD, demonstrating that despite guidelines recommending against their use, a substantial proportion of CKD patients continue to receive NSAIDs.”
BackgroundAntihypertensive treatment and the prevention of dementia: further insights from the Syst-Eur trial
Hansson, L. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917030-00001 · Cited by 32
Lombardi, N., Crescioli, G., Bettiol, A., Tuccori, M., Capuano, A., Bonaiuti, R., Mugelli, A., Venegoni, M., Vighi, G. D., Vannacci, A., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00412 · Cited by 32 · cited 2×
“4% of emergency department visits resulting in hospitalizations [16].”
BackgroundFacing acid–base disorders in the third millennium – the Stewart approach revisited
Honoré, P. M., Kishen, R., Jacobs, R., Joannès-Boyau, O., Waele, E. D., Regt, J. D., Gorp, V. V., Boer, W., & Spapen, H. D. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s62126 · Cited by 30
Hwang, A. Y., Dave, C. V., & Smith, S. M. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy118 · Cited by 26 · cited 1×
“This is usually more frequent in patients with certain comorbidities: in particular, in hypertensive subjects NSAID therapy may lead to intensification of anti-hypertensive regimen [95].”
BackgroundSex Differences in Effects and Use of Anti-inflammatory Drugs
Demyanets, S., & Wojta, J. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-30726-3_20 · Cited by 21 · cited 1×
“However, the pharmacological mechanisms underlying the gender-driven NSAID responses remain elusive [60].”
BackgroundZampolini, M., Stucki, G., Giustini, A., & Négrini, S. (2020) · European Journal of Physical and Rehabilitation Medicine · doi:10.23736/s1973-9087.19.06110-0 · Cited by 20 · cited 1×
“‘‘the set of propositions, elaborated by the rehabilitation team, coordinated by the medical doctor specialist’’) [49].”
BackgroundSavarino, V., Sandro, G., Zentilin, M. P., Cimmino, M. A., Parisi, M., Mele, M. R., Pivari, M., Bisso, G., & Celle, G. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018834301901 · Cited by 19
Self-citationTopical Nonsteroidal Anti-inflammatory Drugs for Acute Musculoskeletal Pain
Derry, S., Wiffen, P. J., & Moore, A. R. (2016) · JAMA · doi:10.1001/jama.2016.0249 · Cited by 16
Wolkin, A. C., Datto, Hellmund, R., & Siddiqui, M. K. (2013) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s41420 · Cited by 15
NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half‐life relevant?
Scharf, S., Kwiatek, R., Ugoni, A., & Christophidis, N. (1998) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1998.tb02077.x · Cited by 14 · cited 1×
“A study conducted in elderly subjects [90] evaluated the presence of gastroduodenal bleeding through the measurement of fecal blood loss and found that it was higher with drugs with a longer plasma half-life, such as naproxen (2.”
BackgroundAntman, E. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.034 · Cited by 12
Cardiovascular effects of NSAIDs.
Sherve, K., Gerard, C. J., Neher, J. O., & Anna, L. S. (2014) · PubMed · Cited by 9
D’Arcy, Y. M., & McCarberg, B. H. (2018) · PubMed · Cited by 3
(1988) · PubMed
Research works printed but not linked: 3
- Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s: The pharmacological basis of therapeutics, 13th edition. New York: McGraw-Hill Education; 2018.
- Burton ME. Applied pharmacokinetics & pharmacodynamics: principles of therapeutic drug monitoring. Philadelphia: Lippincott Williams & Wilkins; 2006.
- Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington DC: National Academies Press; 2001. http://www.ncbi.nlm.nih.gov/books/NBK222274/. Accessed 25 Jun 2019. 25057539
Cited by
Tschon, M., Contartese, D., Pagani, S., Borsari, V., & Fini, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143178 · Cited by 245
Izquierdo, M., de Souto Barreto, P., Arai, H., Bischoff-Ferrari, H. A., Cadore, E. L., Cesari, M., Chen, L.-K., Coen, P. M., Courneya, K. S., Duque, G., et al. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2024.100401 · Cited by 273
Injectable Drug Delivery Systems for Osteoarthritis and Rheumatoid Arthritis
Bruno, M. C., Cristiano, M. C., Celia, C., d’Avanzo, N., Mancuso, A., Paolino, D., Wolfram, J., & Fresta, M. (2022) · ACS Nano · doi:10.1021/acsnano.2c06393 · Cited by 170
Adhesive hydrogels in osteoarthritis: from design to application
Duan, W., Zhang, L., Bohara, R. A., Martín‐Saldaña, S., Yang, F., Zhao, Y., Xie, Y., Bu, Y., & Pandit, A. S. (2023) · Military Medical Research · doi:10.1186/s40779-022-00439-3 · Cited by 120
“Corticosteroids are known to bring adverse effects such as infection and bone loss [214].”
BackgroundAziziaram, Z., Bilal, I., Zhong, Y., Mahmod, A. K., & Roshandel, R. (2021) · Cellular Molecular and Biomedical Reports · doi:10.55705/cmbr.2021.138879.1001 · Cited by 84
Metadata
- Authors
- Magni, A., Agostoni, P., Bonezzi, C., Massazza, G., Menè, P., Savarino, V., & Fornasari, D.
- Affiliations
- University of Milan (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- University of Genoa (IT)
- Corresponding author
- Fornasari, Diego
- Venue
- Pain and Therapy
- Published
- 2021-04-19
- Volume
- 10
- Issue
- 2
- Pages
- 783-808
- ISSN
- 2193-651X (ISSN-L)
- 2193-8237
- PMC
- PMC8586433
- OpenAlex
- W3156408207
- Cited by
- 201
- References
- 106
- Citations by year
- 2026: 42 · 2025: 64 · 2024: 46 · 2023: 26 · 2022: 14 · 2021: 9
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Pain and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by-nc)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by-nc)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc)
- Funders
- Alfasigma SpA
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- osteoarthritis, nonsteroidal anti-inflammatory drugs, NSAID selection, NSAID safety, cardiovascular adverse events, gastrointestinal adverse effects, renal adverse effects, drug-drug interactions, polypharmacy, non-pharmacological treatment, rehabilitation medicine, chronic inflammatory pain, medication adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.